Pain Management · OpioidRegulatory Approvalregulatorynear-term

FDA Approval for Methadone Hydrochloride by Sun Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Sun Pharma6 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/24/2026, 6:32:41 PM

Assessment confidence: 50% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The FDA's approval of Methadone Hydrochloride by Sun Pharma is significant as it strengthens their competitive position in the opioid pain management market. This development necessitates close monitoring of market dynamics and potential competitive responses. Regulatory context from FDA (FDA AP — METHADONE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 13 ranked evidence items (2 high-relevance).

Strategic Assessment

The strongest clinical anchor is Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 8 regulatory and 1 competitive items passed relevance filtering for Sun Pharma. The approval could lead to increased market share for Sun Pharma in the opioid segment, impacting pricing strategies and overall revenue potential.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). This approval may enhance Sun Pharma's position in the opioid market, particularly in pain management therapies.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — METHADONE HYDROCHLORIDE (SUPPL) (FDA). Entity match (methadone hydrochloride); Regulatory pathway relevance (nda). This approval indicates compliance with FDA standards, which may influence future submissions and approvals in the opioid category.

Key Risks

Elevated medium regulatory exposure for Sun Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to increased market share for Sun Pharma in the opioid segment, impacting pricing strategies and overall revenue potential.
The implications of this approval on market share and pricing strategies in the opioid segment.

What Would Change This Assessment

This becomes more urgent if Monitor for market launch details and any competitive responses from other opioid manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHADONE HYDROCHLORIDE INTENSOL (SUPPL)
FDAmedium relevance
Entity match (methadone hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIPHENHYDRAMINE HYDROCHLORIDE (ORIG)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source

Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Human Experimental Models of Pain (HEMP)
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Comparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control
ClinicalTrials.govmedium relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
FDA Approves Tzield for Pediatric Stage 3 Type I Diabetes
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Sun Pharma
Methadone Hydrochloride

Commercial impact

medium

The approval could lead to increased market share for Sun Pharma in the opioid segment, impacting pricing strategies and overall revenue potential.

Regulatory impact

medium

This approval indicates compliance with FDA standards, which may influence future submissions and approvals in the opioid category.

What to watch

Monitor for market launch details and any competitive responses from other opioid manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.